Published in Stroke on March 30, 2006
Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther Adv Neurol Disord (2008) 1.12
Synergistic neuroprotective therapies with hypothermia. Semin Fetal Neonatal Med (2010) 1.05
Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain. Biol Psychiatry (2007) 0.96
Migraine prophylaxis, ischemic depolarizations, and stroke outcomes in mice. Stroke (2014) 0.95
Ketogenic diet prevents cardiac arrest-induced cerebral ischemic neurodegeneration. J Neural Transm (Vienna) (2008) 0.94
Molecular pharmacology in a simple model system: implicating MAP kinase and phosphoinositide signalling in bipolar disorder. Semin Cell Dev Biol (2010) 0.87
New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord (2009) 0.87
Ischemic stroke injury is mediated by aberrant Cdk5. J Neurosci (2014) 0.85
Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy. Int J Mol Sci (2015) 0.84
Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI). BMC Pediatr (2012) 0.81
Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats. Childs Nerv Syst (2014) 0.79
Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget (2015) 0.78
Small molecule anticonvulsant agents with potent in vitro neuroprotection. J Mol Neurosci (2012) 0.77
Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes. Neuroreport (2016) 0.76
Protective role of Kv7 channels in oxygen and glucose deprivation-induced damage in rat caudate brain slices. J Cereb Blood Flow Metab (2015) 0.76
Perinatal brain damage: The term infant. Neurobiol Dis (2015) 0.76
The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion. PLoS One (2013) 0.76
Early intervention in bipolar disorder, part II: therapeutics. Early Interv Psychiatry (2008) 0.76
Valproic Acid Protects Primary Dopamine Neurons from MPP(+)-Induced Neurotoxicity: Involvement of GSK3β Phosphorylation by Akt and ERK through the Mitochondrial Intrinsic Apoptotic Pathway. Biomed Res Int (2017) 0.75
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood (2007) 6.03
Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci (2007) 3.64
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord (2009) 3.56
Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A (2007) 3.50
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron (2005) 3.30
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci (2008) 2.87
An isochore map of human chromosomes. Genome Res (2006) 2.36
Insomnia in maintenance haemodialysis patients. Nephrol Dial Transplant (2002) 2.29
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A (2009) 2.28
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci (2007) 2.19
Ischemic bilateral hippocampal dysfunction during transient global amnesia. Neurology (2007) 2.10
Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J (2009) 1.95
Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia (2009) 1.93
Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci U S A (2004) 1.79
Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. Gene (2004) 1.78
The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease. J Neurosci (2011) 1.76
Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord (2014) 1.76
Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain (2011) 1.75
Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci (2003) 1.66
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood (2009) 1.65
A substrate trapping mutant form of striatal-enriched protein tyrosine phosphatase prevents amphetamine-induced stereotypies and long-term potentiation in the striatum. Biol Psychiatry (2008) 1.63
Genomic GC level, optimal growth temperature, and genome size in prokaryotes. Biochem Biophys Res Commun (2006) 1.61
Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant (2012) 1.61
Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur J Neurosci (2009) 1.59
Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.59
Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. J Inherit Metab Dis (2011) 1.57
Interleukin-1β causes anxiety by interacting with the endocannabinoid system. J Neurosci (2012) 1.55
Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leukoc Biol (2003) 1.55
TNF-α-mediated anxiety in a mouse model of multiple sclerosis. Exp Neurol (2012) 1.55
Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PLoS One (2013) 1.50
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol (2010) 1.50
Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry (2007) 1.48
Correlations between genomic GC levels and optimal growth temperatures in prokaryotes. FEBS Lett (2004) 1.48
Cyclic vomiting syndrome, migraine, and epilepsy: a common underlying disorder? Headache (2003) 1.47
Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. J Neuroimmunol (2007) 1.47
First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging (2015) 1.47
SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain (2010) 1.45
Loss of striatal cannabinoid CB1 receptor function in attention-deficit / hyperactivity disorder mice with point-mutation of the dopamine transporter. Eur J Neurosci (2011) 1.45
Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache (2006) 1.45
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci (2002) 1.40
The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci (2003) 1.39
The evolution of isochore patterns in vertebrate genomes. BMC Genomics (2009) 1.38
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
Dopamine excites fast-spiking interneurons in the striatum. J Neurophysiol (2002) 1.36
Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One (2010) 1.36
The importance of drug interactions in epilepsy therapy. Epilepsia (2002) 1.36
Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain (2009) 1.35
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci (2006) 1.34
The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol (2012) 1.34
The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons. Mol Cell Neurosci (2007) 1.33
Mutations in the ER-shaping protein reticulon 2 cause the axon-degenerative disorder hereditary spastic paraplegia type 12. J Clin Invest (2012) 1.32
Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci (2003) 1.31
Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry (2008) 1.31
Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci (2009) 1.27
FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood (2004) 1.27
Localization of the gene-richest and the gene-poorest isochores in the interphase nuclei of mammals and birds. Gene (2002) 1.27
Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol (2003) 1.26
Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord (2005) 1.26
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord (2011) 1.25
The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci (2007) 1.23
Replication timing, chromosomal bands, and isochores. Proc Natl Acad Sci U S A (2008) 1.22
Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis. FASEB J (2003) 1.22
Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol (2014) 1.20
Synaptic dysfunction in Parkinson's disease. Adv Exp Med Biol (2012) 1.20
Involvement of transient receptor potential-like channels in responses to mGluR-I activation in midbrain dopamine neurons. Eur J Neurosci (2003) 1.19
Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity. Ann Neurol (2011) 1.19
Representing GC variation along eukaryotic chromosomes. Gene (2004) 1.18
Effects of anodal transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis. J Pain (2009) 1.18
The new genes of rice: a closer look. Trends Plant Sci (2004) 1.17